{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T23:24:01Z","timestamp":1789773841705,"version":"4.0.1"},"reference-count":40,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Cancer J"],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:sec>\n            <jats:title>Purpose<\/jats:title>\n            <jats:p>Chemoradiation-induced lymphopenia is common and associated with poorer survival in multiple solid malignancies. However, the association between chemoradiation-related lymphopenia and survival outcomes in rectal cancer is yet unclear. The objective of this study was to evaluate the prognostic impact of lymphopenia and its predictors in patients with rectal cancer undergoing neoadjuvant chemoradiation.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>The inclusion criteria for this single-institution retrospective study were as follows: (1) biopsy-proven diagnosis of rectal adenocarcinoma, (2) receipt of neoadjuvant chemoradiation followed by surgery, and (3) absolute lymphocyte count available prior to and within 12 weeks of chemoradiation. In general, chemoradiation consisted of 5-fluorouracil or capecitabine and radiotherapy with 50.4 Gy over 28 fractions. Lymphopenia was graded according to the Common Terminology Criteria for Adverse Events version 5.0. The primary variable of interest was absolute lymphocyte count nadir within 12 weeks of chemoradiation, dichotomized by &lt;500\/\u03bcL (grade 3 or worse lymphopenia). The primary endpoint was overall survival. Cox modeling and Kaplan-Meier methods were used to perform survival analyses.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>A total of 193 patients were identified with a median follow-up of 68 months. Overall clinical stage was 2 in 21% and 3 in 76%. Median baseline lymphocyte count for the entire cohort was 1700\/\u03bcL. One hundred ten patients (57%) experienced chemoradiation-related severe lymphopenia. Pathologic complete response rate was 21%; 83% received adjuvant chemotherapy. Lower baseline lymphocyte count was significantly associated with increased risk for chemoradiation-related severe lymphopenia (odds ratio, 1.71). On multivariable Cox regression analysis, chemoradiation-related severe lymphopenia was significantly associated with worse disease-free survival (hazard ratio, 2.64) and overall survival (hazard ratio, 4.32). Five-year overall survival was 79% versus 92%, and 5-year disease-free survival was 70% versus 86% in the cohort that experienced versus did not experience severe lymphopenia, respectively.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Discussion<\/jats:title>\n            <jats:p>Chemoradiation-induced lymphopenia is common and a prognostic marker of poorer survival in rectal cancer. Closer observation in high-risk patients and treatment modifications may be potential approaches to mitigating treatment-related lymphopenia. Our findings also suggest an important role of the host immunity in rectal cancer outcomes and support future studies investigating ways to reduce treatment-induced lymphopenia.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ppo.0000000000000749","type":"journal-article","created":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T13:00:10Z","timestamp":1737550810000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Severe Lymphopenia Predicts Poorer Survival in Patients With Rectal Cancer Undergoing Neoadjuvant Chemoradiation"],"prefix":"10.1097","volume":"31","author":[{"given":"Daniel W.","family":"Kim","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elise M.","family":"Cai","sequence":"additional","affiliation":[{"name":"Stanford School of Medicine, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David P.","family":"Ryan","sequence":"additional","affiliation":[{"name":"Medical Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aparna R.","family":"Parikh","sequence":"additional","affiliation":[{"name":"Medical Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill N.","family":"Allen","sequence":"additional","affiliation":[{"name":"Medical Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce J.","family":"Giantonio","sequence":"additional","affiliation":[{"name":"Medical Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David L.","family":"Berger","sequence":"additional","affiliation":[{"name":"Department of Surgery, Massachusetts General Hospital, Boston, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroko","family":"Kunitake","sequence":"additional","affiliation":[{"name":"Department of Surgery, Massachusetts General Hospital, Boston, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rocco","family":"Ricciardi","sequence":"additional","affiliation":[{"name":"Department of Surgery, Massachusetts General Hospital, Boston, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James C.","family":"Cusack","sequence":"additional","affiliation":[{"name":"Department of Surgery, Massachusetts General Hospital, Boston, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah J.","family":"Roberts","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodore S.","family":"Hong","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer Y.","family":"Wo","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"bib1-20250122","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1136\/gutjnl-2015-310912","article-title":"Global patterns and trends in colorectal cancer incidence and mortality","volume":"66","year":"2017","journal-title":"Gut"},{"key":"bib2-20250122","first-page":"546","article-title":"Neoadjuvant combined-modality therapy for locally advanced rectal cancer and its future direction","volume":"30","year":"2016","journal-title":"Oncology (Williston Park)"},{"key":"bib3-20250122","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/ags3.12389","article-title":"Advances in the treatment of locally advanced rectal cancer","volume":"5","year":"2021","journal-title":"Ann Gastroenterol Surg"},{"key":"bib4-20250122","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1056\/NEJMoa040694","article-title":"Preoperative versus postoperative chemoradiotherapy for rectal cancer","volume":"351","year":"2004","journal-title":"N Engl J Med"},{"key":"bib5-20250122","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa2303269","article-title":"Preoperative treatment of locally advanced rectal cancer","volume":"389","year":"2023","journal-title":"N Engl J Med"},{"key":"bib6-20250122","doi-asserted-by":"crossref","first-page":"4620","DOI":"10.1200\/JCO.2006.06.7629","article-title":"Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3\u20134 rectal cancers: results of FFCD 9203","volume":"24","year":"2006","journal-title":"JCO"},{"key":"bib7-20250122","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1200\/JCO.2013.54.3769","article-title":"Tumor regression grading after preoperative chemoradiotherapy for locally advanced rectal carcinoma revisited: updated results of the CAO\/ARO\/AIO-94 trial","volume":"32","year":"2014","journal-title":"JCO"},{"key":"bib8-20250122","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1080\/07357907.2018.1499028","article-title":"Severe treatment-related lymphopenia in patients with newly diagnosed rectal cancer","volume":"36","year":"2018","journal-title":"Cancer Invest"},{"key":"bib9-20250122","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ijrobp.2017.05.037","article-title":"Lymphocyte nadir and esophageal cancer survival outcomes after chemoradiation therapy","volume":"99","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4_suppl","key":"bib10-20250122","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1200\/JCO.2020.38.4_suppl.3","article-title":"Chemoradiation-related lymphopenia and its association with survival in patients with anal cancer","volume":"38","year":"2020","journal-title":"JCO"},{"key":"bib11-20250122","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.radonc.2017.11.028","article-title":"Severe lymphopenia during neoadjuvant chemoradiation for esophageal cancer: a propensity matched analysis of the relative risk of proton versus photon-based radiation therapy","volume":"128","year":"2018","journal-title":"Radiother Oncol"},{"key":"bib12-20250122","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1007\/s00066-019-01462-5","article-title":"Acute severe lymphopenia by radiotherapy is associated with reduced overall survival in hepatocellular carcinoma","volume":"195","year":"2019","journal-title":"Strahlenther Onkol"},{"key":"bib13-20250122","first-page":"83","article-title":"Splenic irradiation contributes to grade \u2265 3 lymphopenia after adjuvant chemoradiation for stomach cancer","volume":"36","year":"2022","journal-title":"Clin Transl Radiat Oncol"},{"key":"bib14-20250122","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.ijrobp.2016.10.046","article-title":"Does unintentional splenic radiation predict outcomes after pancreatic cancer radiation therapy?","volume":"97","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"bib15-20250122","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/COC.0b013e3182940ff9","article-title":"The association between chemoradiation-related lymphopenia and clinical outcomes in patients with locally advanced pancreatic adenocarcinoma","volume":"38","year":"2015","journal-title":"Am J Clin Oncol"},{"key":"bib16-20250122","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.ijrobp.2015.11.026","article-title":"Lymphocyte-sparing effect of stereotactic body radiation therapy in patients with unresectable pancreatic cancer","volume":"94","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"bib17-20250122","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1007\/s00280-011-1610-3","article-title":"Pre-treatment lymphopenia as a prognostic biomarker in colorectal cancer patients receiving chemotherapy","volume":"68","year":"2011","journal-title":"Cancer Chemother Pharmacol"},{"key":"bib18-20250122","first-page":"153303381878006","article-title":"Absolute lymphocyte count in preoperative chemoradiotherapy for rectal cancer: changes over time and prognostic significance","volume":"17","year":"2018","journal-title":"Technol Cancer Res Treat"},{"key":"bib19-20250122","doi-asserted-by":"crossref","first-page":"960","DOI":"10.3389\/fonc.2019.00960","article-title":"Higher levels of pre-operative peripheral lymphocyte count is a favorable prognostic factor for patients with stage I and II rectal cancer","volume":"9","year":"2019","journal-title":"Front Oncol"},{"key":"bib20-20250122","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1159\/000492340","article-title":"Combined pre- and postoperative lymphocyte count accurately predicts outcomes of patients with colorectal cancer","volume":"36","year":"2019","journal-title":"Dig Surg"},{"key":"bib21-20250122","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1186\/s12957-019-1747-9","article-title":"Association of pre-surgery to pre-radiotherapy lymphocyte counts ratio with disease-free survival in rectal cancer patients receiving neoadjuvant concurrent chemoradiotherapy","volume":"17","year":"2019","journal-title":"World J Surg Oncol"},{"key":"bib22-20250122","doi-asserted-by":"crossref","first-page":"232","DOI":"10.4143\/crt.2014.351","article-title":"Sustaining blood lymphocyte count during preoperative chemoradiotherapy as a predictive marker for pathologic complete response in locally advanced rectal cancer","volume":"48","year":"2016","journal-title":"Cancer Res Treat"},{"key":"bib23-20250122","doi-asserted-by":"crossref","first-page":"7566","DOI":"10.1038\/s41598-023-34145-4","article-title":"Severe lymphopenia as a prognostic factor in rectal cancer patients receiving adjuvant chemoradiotherapy: a retrospective study","volume":"13","year":"2023","journal-title":"Sci Rep"},{"key":"bib24-20250122","doi-asserted-by":"crossref","first-page":"1138299","DOI":"10.3389\/fonc.2023.1138299","article-title":"Can lymphocytes serve as a predictor of response to preoperative chemoradiation therapy for locally advanced rectal cancer?","volume":"13","year":"2023","journal-title":"Front Oncol"},{"key":"bib25-20250122","doi-asserted-by":"crossref","first-page":"e11435","DOI":"10.1097\/MD.0000000000011435","article-title":"Reduction of circulating lymphocyte count is a predictor of good tumor response after neoadjuvant treatment for rectal cancer","volume":"97","year":"2018","journal-title":"Medicine"},{"key":"bib26-20250122","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1046\/j.1537-2995.1981.21481275998.x","article-title":"The effects of irradiation on blood components","volume":"21","year":"1981","journal-title":"Transfusion"},{"key":"bib27-20250122","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1186\/s12885-019-6220-1","article-title":"Lymphocyte-sparing effect of stereotactic body radiation therapy compared to conventional fractionated radiation therapy in patients with locally advanced pancreatic cancer","volume":"19","year":"2019","journal-title":"BMC Cancer"},{"issue":"suppl","key":"bib28-20250122","first-page":"abstr e18513","article-title":"Lymphopenia as a predictor of survival in chemoradiation (CRT)\u2013treated stage III non\u2013small cell lung cancer (NSCLC)","volume":"33","year":"2019","journal-title":"J Clin Oncol"},{"key":"bib29-20250122","doi-asserted-by":"crossref","first-page":"808964","DOI":"10.3389\/fimmu.2021.808964","article-title":"Tumor-infiltrating lymphocytes in colorectal cancer: the fundamental indication and application on immunotherapy","volume":"12","year":"2022","journal-title":"Front Immunol"},{"key":"bib30-20250122","first-page":"djw027","article-title":"Tumor-infiltrating lymphocytes, Crohn's-like lymphoid reaction, and survival from colorectal cancer","volume":"108","year":"2016","journal-title":"J Natl Cancer Inst"},{"key":"bib31-20250122","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1038\/s41598-020-60255-4","article-title":"The prognostic implications of tumor infiltrating lymphocytes in colorectal cancer: a systematic review and meta-analysis","volume":"10","year":"2020","journal-title":"Sci Rep"},{"key":"bib32-20250122","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1056\/NEJMoa2017699","article-title":"Pembrolizumab in microsatellite-instability\u2013high advanced colorectal cancer","volume":"383","year":"2020","journal-title":"N Engl J Med"},{"key":"bib33-20250122","doi-asserted-by":"crossref","first-page":"3485","DOI":"10.1200\/JCO.2010.28.3994","article-title":"Phase II study of the anti\u2013cytotoxic T-lymphocyte\u2013associated antigen 4 monoclonal antibody, tremelimumab, in patients with refractory metastatic colorectal cancer","volume":"28","year":"2010","journal-title":"JCO"},{"key":"bib34-20250122","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S1470-2045(22)00197-8","article-title":"Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair\u2013deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study","volume":"23","year":"2022","journal-title":"Lancet Oncol"},{"key":"bib35-20250122","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1200\/JCO.21.01015","article-title":"First-line nivolumab plus low-dose ipilimumab for microsatellite instability-high\/mismatch repair\u2013deficient metastatic colorectal cancer: the phase II CheckMate 142 study","volume":"40","year":"2022","journal-title":"JCO"},{"key":"bib36-20250122","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1200\/JCO.22.01351","article-title":"Neoadjuvant pembrolizumab in localized microsatellite instability high\/deficient mismatch repair solid tumors","volume":"41","year":"2023","journal-title":"JCO"},{"issue":"4_suppl","key":"bib37-20250122","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1200\/JCO.2023.41.4_suppl.7","article-title":"Long-term results from NRG-GI002: a phase II clinical trial platform using total neoadjuvant therapy (TNT) in locally advanced rectal cancer (LARC)","volume":"41","year":"2023","journal-title":"JCO"},{"issue":"4_suppl","key":"bib38-20250122","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1200\/JCO.2023.41.4_suppl.108","article-title":"Survival outcomes and functional results of VOLTAGE-A: preoperative chemoradiotherapy (CRT) and consolidation nivolumab (nivo) in patients (pts) with both microsatellite stable (MSS) and microsatellite instability\u2013high (MSI-H) locally advanced rectal cancer (LARC)","volume":"41","year":"2023","journal-title":"JCO"},{"key":"bib39-20250122","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/S1470-2045(21)00079-6","article-title":"Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial","volume":"22","year":"2021","journal-title":"Lancet Oncol"},{"issue":"17_suppl","key":"bib40-20250122","doi-asserted-by":"crossref","first-page":"LBA3504","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA3504","article-title":"Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiation in patients with locally advanced rectal cancer: 7-year results of PRODIGE 23 phase III trial, a UNICANCER GI trial","volume":"41","year":"2023","journal-title":"JCO"}],"container-title":["The Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PPO.0000000000000749","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T13:00:24Z","timestamp":1737550824000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PPO.0000000000000749"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/ppo.0000000000000749","relation":{},"ISSN":["1540-336X","1528-9117"],"issn-type":[{"value":"1540-336X","type":"electronic"},{"value":"1528-9117","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]}}}